Seres Therapeutics, Inc. (MCRB) Key Metrics
MCRB valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $24.7M
- Enterprise value
- $81.4M
- P/E (TTM)
- —
- Forward P/E
- 10.3
- PEG ratio
- —
- Price / sales
- 13.1 10-yr median 9.6
- Price / book
- 1.2 10-yr median 8.1
- EV / EBITDA
- 3.3
- Dividend yield
- —
- Beta
- 0.31
MCRB key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsMCRB valuation Price multiples at each fiscal year-end price.
MCRB returns How much profit the business earns on the capital it uses.
MCRB per-share figures Results divided by the shares outstanding at year-end.
MCRB financial health Debt, liquidity and how easily interest is covered.
MCRB efficiency & capital use Working capital cycle and where the cash goes.
MCRB valuation history
MCRB returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
MCRB debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
MCRB cash returned to shareholders
MCRB price vs earnings per share
MCRB key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $132.0M | $129.1M | $179.2M | $605.2M | $763.9M | $1.95B | $195.4M | $184.2M | $410.2M | — |
| Enterprise value | $169.2M | $190.0M | $250.0M | $586.5M | $522.4M | $1.74B | $145.4M | $105.6M | $269.2M | — |
| P/E ratio | 23.2 | — | — | — | — | — | — | — | — | — |
| Price / sales | 167.3 | — | 1.4 | 84.9 | 5.3 | 58.9 | 5.7 | 6.5 | 12.8 | — |
| Price / book | 3.0 | 9.4 | — | 56.1 | 5.8 | 11.2 | — | — | 6.8 | — |
| Price / free cash flow | 152.6 | — | — | — | — | — | — | — | — | — |
| Price / operating cash flow | 118.2 | — | — | — | 114.2 | — | — | — | — | — |
| EV / sales | 214.4 | — | 2.0 | 82.3 | 3.6 | 52.4 | 4.2 | 3.7 | 8.4 | — |
| EV / EBITDA | 17.2 | — | — | — | — | — | — | — | — | — |
| EV / free cash flow | 195.6 | — | — | — | — | — | — | — | — | — |
| Earnings yield | 4.3% | −113.5% | −63.5% | −41.3% | −8.6% | −4.6% | −36.0% | −53.7% | −21.8% | — |
| Free cash flow yield | 0.7% | −115.4% | −69.9% | −39.4% | −0.4% | −4.8% | −39.7% | −35.2% | −19.6% | — |
| Dividend yield | — | — | — | — | — | — | — | — | 0.0% | — |
| Shareholder yield (dividends + buybacks) | — | — | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | — |
| Share price at fiscal year-end | $14.88 | $16.62 | $28.00 | $112.00 | $166.60 | $490.00 | $69.00 | $90.40 | $202.80 | $198.00 |
| Per share | ||||||||||
| Revenue per share | $0.09 | $0.00 | $19.74 | $1.32 | $31.61 | $8.33 | $12.18 | $13.88 | $15.87 | — |
| Earnings per share | $0.64 | −$18.86 | −$17.77 | −$46.29 | −$14.30 | −$22.34 | −$24.81 | −$48.57 | −$44.19 | — |
| Operating cash flow per share | $0.13 | −$19.13 | −$18.34 | −$42.34 | $1.46 | −$23.46 | −$27.02 | −$30.85 | −$37.34 | — |
| Free cash flow per share | $0.10 | −$19.17 | −$19.58 | −$44.16 | −$0.63 | −$23.61 | −$27.37 | −$31.80 | −$39.65 | — |
| Cash per share | $5.16 | $3.96 | $19.99 | $33.56 | $63.40 | $63.57 | $33.47 | $42.13 | $74.16 | — |
| Book value per share | $4.99 | $1.77 | −$7.01 | $2.00 | $28.68 | $43.80 | −$17.06 | −$23.58 | $30.01 | — |
| Tangible book value per share | $4.99 | $1.77 | −$7.01 | $2.00 | $28.68 | $43.80 | −$17.06 | −$23.58 | $30.01 | — |
| Dividends per share | — | — | — | — | — | — | — | — | $0.00 | — |
| Capex per share | $0.03 | $0.05 | $1.25 | $1.82 | $2.09 | $0.15 | $0.35 | $0.95 | $2.31 | — |
| Debt per share | $9.35 | $11.79 | $31.06 | $30.09 | $10.73 | $10.22 | $15.81 | $3.56 | $4.44 | — |
| Shares outstanding | 8.9M | 7.8M | 6.4M | 5.4M | 4.6M | 4.0M | 2.8M | 2.0M | 2.0M | — |
| Change in shares outstanding | +14.2% | +21.4% | +18.4% | +17.9% | +14.9% | +40.8% | +39.0% | +0.7% | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | 19.6% | — | — | −351.6% | −42.8% | −141.0% | — | — | −92.5% | −54.2% |
| Return on invested capital (ROIC) | −95.1% | −190.5% | — | — | — | — | — | — | — | — |
| Return on assets (ROA) | 4.1% | −58.8% | −32.2% | −71.1% | −18.8% | −37.5% | −55.6% | −63.8% | −38.7% | −37.4% |
| Return on tangible assets | 4.1% | −104.8% | −31.7% | −71.7% | −18.5% | −26.0% | −53.1% | −82.1% | −47.2% | −33.6% |
| Free cash flow margin | 109.6% | — | −99.2% | — | −2.0% | −283.6% | −224.7% | −229.2% | −249.8% | 103.0% |
| Income quality (OCF / net income) | 0.20 | — | — | — | — | — | — | — | — | — |
| Financial health | ||||||||||
| Total debt | $83.0M | $91.6M | $198.8M | $162.6M | $49.2M | $40.8M | $44.8M | $7.2M | $9.0M | $10.7M |
| Cash & short-term investments | $45.8M | $30.8M | $128.0M | $181.3M | $290.7M | $253.6M | $94.8M | $85.8M | $150.0M | $193.2M |
| Net debt | $37.2M | $60.8M | $70.8M | −$18.8M | −$241.5M | −$212.8M | −$50.0M | −$78.6M | −$141.0M | −$182.5M |
| Debt / equity | 1.88 | 6.65 | — | 15.08 | 0.37 | 0.23 | — | — | 0.15 | 0.08 |
| Debt / assets | 0.60 | 0.66 | 0.55 | 0.47 | 0.14 | 0.12 | 0.34 | 0.06 | 0.05 | 0.04 |
| Net debt / EBITDA | 3.78 | — | — | — | — | — | — | — | — | — |
| Current ratio | 2.56 | 0.94 | 1.78 | 2.28 | 3.69 | 5.79 | 2.18 | 2.20 | 4.90 | 6.51 |
| Quick ratio | 2.56 | 0.94 | 1.48 | 2.28 | 3.69 | 5.79 | 2.82 | 2.20 | 4.90 | 6.51 |
| Interest coverage | — | — | -14.8 | -29.9 | -22.2 | -30.1 | -143.2 | -85.6 | -57.5 | -95.8 |
| Working capital | $30.1M | −$2.5M | $76.8M | $109.2M | $221.4M | $222.4M | $54.2M | $50.6M | $123.5M | $167.9M |
| Invested capital | $81.4M | $74.6M | $26.0M | −$8.0M | −$110.0M | −$38.1M | −$98.4M | −$126.6M | −$80.3M | −$49.9M |
| Tangible asset value | $44.2M | $13.8M | −$44.9M | $10.8M | $131.5M | $174.8M | −$48.3M | −$48.0M | $60.7M | $132.6M |
| Net current asset value | −$44.6M | −$87.4M | −$228.0M | −$143.2M | $80.3M | $100.6M | −$80.6M | −$75.9M | $26.3M | $58.4M |
| Graham number | $8.49 | — | — | — | — | — | — | — | — | — |
| Graham net-net per share | −$5.40 | −$11.80 | −$39.71 | −$28.99 | $14.69 | $23.18 | −$35.11 | −$40.59 | $10.46 | — |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | — | — | — | — | — | $0 | $0 |
| Share buybacks (net) | — | — | — | $0 | $0 | $0 | $0 | $197,000 | $33,000 | $0 |
| Dividends + buybacks / free cash flow | — | — | — | — | — | — | — | — | — | 0.0% |
| Capex / revenue | 31.9% | — | 6.3% | 137.8% | 6.6% | 1.8% | 2.9% | 6.9% | 14.6% | 98.7% |
| Capex / operating cash flow | 22.6% | — | — | — | 143.0% | — | — | — | — | 48.9% |
| Capex / depreciation | 0.06 | 0.07 | 1.28 | 1.48 | 1.61 | 0.09 | 0.13 | 0.25 | 0.64 | 5.11 |
| Stock-based compensation / revenue | 1,373.9% | — | 27.0% | 357.5% | 14.0% | 26.6% | 24.2% | 58.9% | 54.1% | 77.4% |
| R&D / revenue | 6,218.0% | — | 93.1% | 1,538.3% | 97.9% | 272.7% | 232.3% | 339.5% | 278.7% | 376.7% |
| SG&A / revenue | 4,962.7% | — | 61.3% | 985.7% | 47.8% | 92.7% | 71.7% | 115.3% | 106.0% | 149.8% |
| Efficiency | ||||||||||
| Days sales outstanding | 1,182.2 | — | 25.1 | — | 11.8 | 61.4 | 18.9 | — | — | — |
| Days of inventory on hand | — | — | 279.7 | — | — | -59.8 | -135.2 | — | — | — |
| Days payables outstanding | 254.4 | 398.9 | 198.9 | 5,666.8 | 22.8 | 17.9 | 25.7 | 25.6 | 29.8 | 28.9 |
| Cash conversion cycle (days) | 927.8 | — | 105.9 | — | -11.0 | -16.3 | -142.0 | — | — | — |
| Receivables turnover | 0.31 | 0.00 | 14.56 | — | 30.88 | 5.95 | 19.33 | — | — | — |
| Payables turnover | 1.43 | 0.92 | 1.83 | 0.06 | 15.99 | 20.41 | 14.22 | 14.27 | 12.24 | 12.63 |
| Inventory turnover | — | — | 1.30 | — | — | — | — | — | — | — |
| Asset turnover | 0.01 | 0.00 | 0.36 | 0.02 | 0.42 | 0.14 | 0.27 | 0.18 | 0.14 | 0.09 |
| Average receivables | $2.6M | $6.7M | $8.7M | — | $4.7M | $5.6M | $1.8M | — | — | — |
| Average payables | $2.9M | $3.9M | $10.5M | $15.6M | $8.9M | $4.4M | $5.6M | $6.7M | $7.3M | $6.5M |
| Average inventory | — | — | $14.8M | $0 | — | −$14.8M | −$29.7M | — | $0 | $0 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from MCRB's annual financial statements (latest annual report filed March 12, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
MCRB valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), Seres Therapeutics traded at 23.2 times earnings. Seres Therapeutics earned a return on equity of 19.6% and a return on invested capital of −95.1% in fiscal 2025. It ended the year with $83.0 million of debt and $45.8 million in cash and short-term investments, net debt of $37.2 million.
See the MCRB income statement, the MCRB chart for price history, or the MCRB stock overview for the latest quote and news.
MCRB key metrics FAQ
What is Seres Therapeutics's P/E ratio?
Seres Therapeutics traded at 23.2 times earnings at the end of fiscal 2025.
What is Seres Therapeutics's EV/EBITDA?
Seres Therapeutics's enterprise value was 17.2 times EBITDA at the end of fiscal 2025 (enterprise value $169.2 million, EBITDA $9.8 million); the current EV/EBITDA is 3.3.
What is Seres Therapeutics's return on equity?
Seres Therapeutics's return on equity (ROE) was 19.6% in fiscal 2025: net income of $5.7 million on average shareholders' equity of $29.0 million.
What is Seres Therapeutics's ROIC?
Seres Therapeutics's return on invested capital was −95.1% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Seres Therapeutics have?
Seres Therapeutics had total debt of $83.0 million at the end of fiscal 2025, a debt-to-equity ratio of 1.88 and $37.2 million of net debt (3.78 times EBITDA).
What is Seres Therapeutics's free cash flow yield?
Seres Therapeutics generated $0.9 million of free cash flow in fiscal 2025, a free cash flow yield of 0.7% on its market value at year-end ($132.0 million).
What is Seres Therapeutics's current ratio?
Seres Therapeutics's current ratio was 2.56 at the end of fiscal 2025: current assets were 2.56 times current liabilities.